Kendall Beck, MD
Gastroenterology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Office
- 1
- Since medical school
- 15 years
- Graduated 2011
Offices
1 location · Regents of the University of California · 706 clinicians in this group
Hospitals listed: UCSF Health Stanyan Hospital · UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Beck’s office at (415) 476-4029 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A122880 · Current
Licensed to practise in California · since 2012 · expires 2028-08-31 · University of Texas Medical School at Houston.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Gastroenterology
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Health St. Mary'S HospitalSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 2 of 5 · 60% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Health St. Mary'S Hospital
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 9 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0 to 1.99) · 413 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.96 (0.58 to 1.34) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 146.74 (92.54 to 200.93) · 30 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.4 · 35 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 51 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.6 · 220 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 9.3 · 165 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 102 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,363 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.02 to 0.46) · 2,530 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.32 (0.12 to 0.53) · 2,519 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.02 (0.73 to 5.31) · 590 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.63 (0 to 3.35) · 238 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.07 (0.43 to 3.7) · 554 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 12.7 (4.19 to 21.21) · 259 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.67 (1.51 to 9.83) · 203 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.7 (0.19 to 3.2) · 168 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.21 (0 to 0.99) · 2,258 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 158 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 61 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.1 · 291 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -3.4 · 251 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 5.5 · 189 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.1 · 213 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.7 to 8.5) · 30 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12 (8.3 to 17.1) · 30 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.5 · 176 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 61 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.1 (9.6 to 17.8) · 192 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 113 cases | No different | Jan 2024 – Dec 2024 |
What patients said (587 patients answered, 20% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 2 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 41% |
| "YES", patients would definitely recommend the hospital | 60% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$70,866
Medicare paid this office $70,866 for 323 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 101 | $23,009 | $228 |
| Long return visit (40+ min) | 71 | $13,046 | $120 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 66 | $5,588 | $85 |
| Biopsy of large bowel using a flexible endoscope | 51 | $5,254 | $103 |
| New patient visit (60+ min) | 20 | $3,318 | $166 |
See all 12 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 101 | $23,009 | $228 |
| Long return visit (40+ min) | 71 | $13,046 | $120 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 66 | $5,588 | $85 |
| Biopsy of large bowel using a flexible endoscope | 51 | $5,254 | $103 |
| New patient visit (60+ min) | 20 | $3,318 | $166 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 15 | $2,851 | $190 |
| Return visit (30+ min) | 27 | $2,284 | $85 |
| New patient visit (45+ min) | 19 | $1,968 | $104 |
| Diagnostic exam of large bowel using a flexible endoscope | 13 | $1,846 | $142 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 78 | $1,616 | $15 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $1,218 | $94 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 85 | $409 | $5 |
Procedures Medicare counted
| Colonoscopy | 84 | More than 75% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 73 | More than 70% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 31 | 47 | 51 | 80 | 85 | 101 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 51 | 68 | 53 | 75 | 68 | 66 |
| Biopsy of large bowel using a flexible endoscope | 46 | 67 | 23 | 49 | 46 | 51 |
| Diagnostic exam of large bowel using a flexible endoscope | 26 | 24 | – | 13 | 20 | 13 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | – | 13 | – | 12 | 15 | 13 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
323 Original Medicare patients in 2024. Average age 69 · Women 63% · Also on Medicaid 28% · Health risk score 1.65. Above the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 63% · Depression 26% · Diabetes 25% · Chronic kidney disease 23% · Cancer 22% · Coronary heart disease 19% · Atrial fibrillation 17% · Heart failure 15% · COPD 11% · Stroke 11% · Dementia 7%.
The office billed $946,844, Medicare allowed $89,521 and paid $70,866; for 715 services of 48 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 323 | 715 | 69 | 1.65 | $946,844 | $70,866 |
| 2023 | 358 | 1,238 | 71 | 1.95 | $990,784 | $78,003 |
| 2022 | 312 | 584 | 71 | 1.69 | $935,070 | $62,789 |
| 2021 | 231 | 414 | 69 | 1.73 | $599,924 | $44,722 |
| 2020 | 335 | 561 | 68 | 1.89 | $903,697 | $67,670 |
| 2019 | 273 | 430 | 68 | 1.87 | $664,096 | $54,793 |
| 2018 | 353 | 570 | 69 | 1.81 | $860,815 | $67,958 |
| 2017 | 146 | 213 | 69 | 1.81 | $315,937 | $26,727 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 84 | $18,987 | $223 |
| Long return visit (40+ min) | 72 | $10,412 | $117 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 66 | $6,570 | $97 |
| Biopsy of large bowel using a flexible endoscope | 45 | $4,964 | $108 |
| New patient visit (60+ min) | 31 | $4,738 | $153 |
| New patient visit (45+ min) | 34 | $3,505 | $103 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $2,816 | $156 |
| Diagnostic exam of large bowel using a flexible endoscope | 20 | $2,766 | $138 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,223 | $117 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 15 | $1,388 | $93 |
| Return visit (30+ min) | 13 | $1,060 | $82 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $857 | $71 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 84 | $398 | $5 |
2022: 17 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 48 | $10,241 | $213 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 32 | $6,996 | $219 |
| Long return visit (40+ min) | 35 | $6,231 | $127 |
| New patient visit (45+ min) | 36 | $4,041 | $112 |
| New patient visit (60+ min) | 23 | $3,791 | $165 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 36 | $3,504 | $95 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 38 | $3,376 | $89 |
| Biopsy of large bowel using a flexible endoscope | 29 | $2,885 | $99 |
| Return visit (30+ min) | 24 | $1,891 | $79 |
| Diagnostic exam of large bowel using a flexible endoscope | 13 | $1,865 | $143 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,675 | $120 |
| Biopsy of large bowel using a flexible endoscope | 20 | $1,578 | $79 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $1,462 | $91 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 12 | $1,220 | $102 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $760 | $63 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 47 | $198 | $4 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 15 | $70 | $5 |
2021: 12 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 34 | $6,968 | $205 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 16 | $3,903 | $230 |
| Long return visit (40+ min) | 21 | $3,462 | $128 |
| Biopsy of large bowel using a flexible endoscope | 23 | $3,176 | $138 |
| New patient visit (45+ min) | 28 | $2,990 | $107 |
| New patient visit (60+ min) | 17 | $2,744 | $161 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,685 | $179 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 25 | $2,457 | $98 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 28 | $2,443 | $87 |
| Return visit (30+ min) | 24 | $2,106 | $75 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $1,477 | $92 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 56 | $261 | $5 |
2020: 16 services
| New patient visit (60+ min) | 54 | $7,267 | $135 |
| Long return visit (40+ min) | 46 | $6,567 | $97 |
| Biopsy of large bowel using a flexible endoscope | 42 | $5,463 | $130 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 24 | $5,367 | $224 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 23 | $5,277 | $229 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $4,535 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $3,743 | $94 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 37 | $3,376 | $91 |
| Biopsy of large bowel using a flexible endoscope | 24 | $2,815 | $113 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 30 | $2,804 | $90 |
| New patient visit (45+ min) | 18 | $1,975 | $110 |
| Diagnostic exam of large bowel using a flexible endoscope | 13 | $1,882 | $145 |
| Diagnostic exam of large bowel using a flexible endoscope | 11 | $1,869 | $170 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $1,800 | $64 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,481 | $123 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $1,235 | $95 |
2019: 15 services
| New patient visit (60+ min) | 44 | $6,625 | $151 |
| Long return visit (40+ min) | 44 | $5,313 | $97 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 16 | $3,747 | $234 |
| Biopsy of large bowel using a flexible endoscope | 23 | $3,577 | $156 |
| Biopsy of large bowel using a flexible endoscope | 23 | $3,407 | $148 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 15 | $3,343 | $223 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,265 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $3,077 | $93 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 28 | $2,694 | $96 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 23 | $2,452 | $107 |
| Diagnostic exam of large bowel using a flexible endoscope | 14 | $2,210 | $158 |
| Diagnostic exam of large bowel using a flexible endoscope | 12 | $1,657 | $138 |
| New patient visit (45+ min) | 14 | $1,614 | $115 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,346 | $122 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $979 | $65 |
2018: 17 services
| Long return visit (40+ min) | 72 | $7,905 | $88 |
| Biopsy of large bowel using a flexible endoscope | 52 | $7,410 | $142 |
| Biopsy of large bowel using a flexible endoscope | 41 | $5,909 | $144 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 21 | $4,870 | $232 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 22 | $4,563 | $207 |
| New patient visit (45+ min) | 40 | $4,299 | $107 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,961 | $180 |
| New patient visit (60+ min) | 27 | $3,449 | $128 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 31 | $3,240 | $105 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 29 | $2,363 | $81 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 23 | $2,223 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $2,131 | $61 |
| Diagnostic exam of large bowel using a flexible endoscope | 12 | $2,005 | $167 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,693 | $121 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $1,668 | $88 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $1,177 | $91 |
| New patient visit (30+ min) | 12 | $808 | $67 |
2017: 5 services
| New patient visit (60+ min) | 22 | $3,206 | $146 |
| Long return visit (40+ min) | 28 | $2,821 | $97 |
| Biopsy of large bowel using a flexible endoscope | 16 | $1,783 | $105 |
| New patient visit (45+ min) | 11 | $1,153 | $105 |
| Biopsy of large bowel using a flexible endoscope | 11 | $1,014 | $92 |
Medicaid work
$8,449 in 2024
Medicaid paid $8,449 for 114 billed services this clinician did in 2024, up to 19 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 59 | $7,798 |
| Telehealth transmission, per minute, professional services bill separately | 55 | $651 |
| 2024 | 114 | 2 | 19 | $8,449 |
| 2023 | 114 | 2 | 16 | $6,373 |
| 2022 | 81 | 4 | 17 | $3,481 |
| 2021 | 136 | 4 | 19 | $6,411 |
| 2020 | 66 | 3 | 15 | $2,772 |
| 2019 | 28 | 2 | 15 | $5,621 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 58 | $5,560 |
| Telehealth transmission, per minute, professional services bill separately | 56 | $813 |
2022
| Long return visit (40+ min) | 12 | $1,531 |
| Return visit (30+ min) | 13 | $795 |
| Telehealth originating site facility fee | 13 | $681 |
| Telehealth transmission, per minute, professional services bill separately | 43 | $475 |
2021
| Long return visit (40+ min) | 28 | $3,384 |
| Telehealth originating site facility fee | 33 | $1,623 |
| Infusion, normal saline solution , 1000 cc | 48 | $758 |
| TISSUE EXAM BY PATHOLOGIST | 27 | $647 |
2020
| Upper gastrointestinal endoscopy with biopsy | 12 | $1,473 |
| Telehealth originating site facility fee | 16 | $819 |
| Telehealth transmission, per minute, professional services bill separately | 38 | $480 |
2019
| COLONOSCOPY AND BIOPSY | 13 | $3,099 |
| Upper gastrointestinal endoscopy with biopsy | 15 | $2,522 |
Drugs they prescribed that Part D paid
$1,488,595
Pharmacies billed $1,488,595 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 307) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
169 generic and fewer than 11 brand-name prescriptions · $1,488,595 in drug cost · 26 antibiotic prescriptions to 15 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Gattex | 17 | $754,153 | $44,362 |
| Stelara | 11 | $295,663 | $26,878 |
| Humira(Cf) | 15 | $123,167 | $8,211 |
| Rinvoq | 16 | $116,906 | $7,307 |
| Xifaxan | 17 | $55,932 | $3,290 |
See all 9 drugs
| Gattex | 17 | $754,153 | $44,362 |
| Stelara | 11 | $295,663 | $26,878 |
| Humira(Cf) | 15 | $123,167 | $8,211 |
| Rinvoq | 16 | $116,906 | $7,307 |
| Xifaxan | 17 | $55,932 | $3,290 |
| Linzess | 17 | $15,379 | $905 |
| Sucralfate | 21 | $1,498 | $71 |
| Omeprazole | 49 | $591 | $12 |
| Pantoprazole | 35 | $341 | $10 |
Year by year
| 2024 | 307 | 103 | 0% (0) | None | $1,488,595 |
| 2023 | 339 | 98 | None | 35% | $1,860,203 |
| 2022 | 249 | 73 | 0% (0) | None | $1,792,405 |
| 2021 | 241 | 73 | 0% (0) | 24% | $1,157,309 |
| 2020 | 314 | 92 | None | 15% | $178,897 |
| 2019 | 150 | 65 | 0% (0) | 21% | $28,631 |
| 2018 | 265 | 95 | 0% (0) | None | $168,866 |
| 2017 | 90 | 37 | None | 22% | $13,459 |
| 2016 | 24 | 11 | None | None | $9,279 |
| 2014 | 24 | None | 0% (0) | None | $1,074 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Gattex | 24 | $1,101,671 | $45,903 |
| Stelara | 17 | $479,216 | $28,189 |
| Xifaxan | 13 | $30,433 | $2,341 |
| Sucralfate | 22 | $2,664 | $121 |
| Omeprazole | 83 | $1,955 | $24 |
| Pantoprazole | 40 | $937 | $23 |
2022: 4 drugs
| Gattex | 37 | $1,623,164 | $43,869 |
| Omeprazole | 64 | $949 | $15 |
| Pantoprazole | 18 | $811 | $45 |
| Sucralfate | 15 | $710 | $47 |
2021: 3 drugs
| Gattex | 26 | $1,112,337 | $42,782 |
| Omeprazole | 81 | $1,406 | $17 |
| Famotidine | 15 | $282 | $19 |
2020: 7 drugs
| Budesonide Ec | 11 | $4,687 | $426 |
| Sucralfate | 18 | $3,064 | $170 |
| Omeprazole | 71 | $978 | $14 |
| Ondansetron | 15 | $710 | $47 |
| Pantoprazole | 15 | $393 | $26 |
| Famotidine | 17 | $291 | $17 |
| Gabapentin | 13 | $175 | $13 |
2019: 2 drugs
| Omeprazole | 37 | $425 | $11 |
| Pantoprazole | 12 | $81 | $7 |
2018: 5 drugs
| Budesonide Ec | 15 | $7,469 | $498 |
| Omeprazole | 67 | $745 | $11 |
| Polyethylene Glycol 3350 | 16 | $568 | $35 |
| Sucralfate | 14 | $408 | $29 |
| Dicyclomine | 19 | $105 | $6 |
Money from drug and device companies
$29 in 2025
| 2025 | 1 | 1 | None | $29 |
| 2024 | 1 | 1 | None | $30 |
| 2023 | 1 | 2 | None | $76 |
| 2022 | 2 | 3 | None | $75 |
| 2021 | 1 | 1 | None | $22 |
| 2020 | 1 | 1 | None | $33 |
| 2019 | 2 | 2 | None | $28 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Gilead Sciences | None | $29 | 1 payment
|
See the published payment
| Gilead Sciences | Meals · 2025-02-07 | None | $29 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $30
| Pfizer | Velsipity | $30 | 1 payment
|
2023: $76
| PENTAX of America | Pentax Medical | $76 | 2 payments
|
2022: $75
| Janssen Biotech | Stelara | $52 | 2 payments
|
| PENTAX of America | Video Processor | $23 | 1 payment
|
2021: $22
| AbbVie | Creon | $22 | 1 payment
|
2020: $33
| Janssen Biotech | Stelara | $33 | 1 payment
|
2019: $28
| Fresenius Kabi USA | Ph-Omegaven | $14 | 1 payment
|
| Janssen Biotech | Stelara | $14 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| ABBVIE INC. · A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study To Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately To Severely Active Ulcerative Colitis · 2022 | Their institution | $82,111 |
| Takeda Pharmaceuticals U.S.A., Inc. · Teduglutide for Treatment of Short Bowel Syndrome in Real World Settings: Center-Based Study in the US and Eu · 2023 | Their institution | $74,316 |
| ABBVIE INC. · A Study To Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis · 2022 | Their institution | $60,620 |
| ABBVIE INC. · A Study To Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis · 2023 | Their institution | $56,866 |
| ABBVIE INC. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (Abt-494) in Subjects With Crohns Disease Who Completed the Studies M14-431 Or M14-433 · 2021 | Their institution | $44,002 |
| ABBVIE INC. · M24-885 - Study of Targeted Therapies for the Treatment of Adult Participants With Moderate To Severe Crohn S Disease (Target Cd) · 2025 | Their institution | $38,823 |
| ABBVIE INC. · A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study To Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately To Severely Active Ulcerative Colitis · 2021 | Their institution | $37,921 |
| Takeda Pharmaceuticals U.S.A., Inc. · Teduglutide and Nutrient Receptor Ligands, By Reducing Intestinal Permeability, Improve Outcomes in Critical Illness · 2022 | Their institution | $35,935 |
| ABBVIE INC. · A Study To Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis · 2024 | Their institution | $35,798 |
| ABBVIE INC. · A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (Abt-494) in Participants With Crohns Disease Who Completed the Studies M14-431 Or M14-433 · 2023 | Their institution | $31,715 |
| AbbVie Inc. · Skyrizi · 2020 | Their institution | $30,929 |
| ABBVIE INC. · A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (Abt-494) in Participants With Crohn Disease Who Completed the Studies M14-431 Or M14-433 · 2024 | Their institution | $23,923 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Phase II Anti Il36r Treatment of Fibrostenotic Cd · 2022 | Their institution | $22,184 |
| AbbVie, Inc. · Rinvoq · 2019 | Their institution | $21,537 |
| ABBVIE INC. · A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (Abt-494) in Participants With Crohnx27s Disease Who Completed the Studies M14-431 Or M14-433 · 2022 | Their institution | $21,125 |
| AbbVie, Inc. · Skyrizi · 2019 | Their institution | $15,910 |
| ABBVIE INC. · A Study of the Efficacy and Safety of Upadacitinib (Abt-494) in Participants With Moderately To Severely Active Crohnx27s Disease Who Have Inadequately Responded To Or Are Intolerant To Biologic Therapy · 2022 | Their institution | $14,227 |
| ABBVIE INC. · A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (Abt-494) in Participants With Crohn Disease Who Completed the Studies M14-431 Or M14-433 · 2025 | Their institution | $12,518 |
| ABBVIE INC. · A Study To Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis · 2025 | Their institution | $12,174 |
| PFIZER INC. · A Phase 2a Multicenter Randomized Doubleblind Placebocontrolled Study With An Open Label Chronic Treatment Period To Evaluate the Efficacy Safety and Pharmacokinetics of Pf06480605 in Adult Participants With Moderate To Severe Crohns Disease · 2022 | Their institution | $10,374 |
| ABBVIE INC. · M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (Abt-494) in Participants With Crohn Disease Who Completed the Studies M14-431 Or M14-433 · 2025 | Their institution | $10,272 |
| ABBVIE INC. · A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study To Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately To Severely Active Ulcerative Colitis · 2023 | Their institution | $10,120 |
| ABBVIE INC. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (Abt-494) in Subjects With Moderately To Severely Active Crohns Disease Who Have Inadequately Responded To Or Are Intolerant To Biologic Therapy · 2021 | Their institution | $9,627 |
| ABBVIE INC. · A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and An Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis · 2021 | Their institution | $6,518 |
| AbbVie Inc. · Rinvoq · 2020 | Their institution | $6,430 |
| ABBVIE INC. · Study of Targeted Therapies for the Treatment of Adult Participants With Moderate To Severe Crohn S Disease (Target Cd) · 2025 | Their institution | $5,023 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Phase II Anti Il36r Treatment of Fibrostenotic Cd · 2023 | Their institution | $3,900 |
| ABBVIE INC. · M16-066 - A Study To Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis · 2025 | Their institution | $3,412 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Phase II Anti Il36r Treatment of Fibrostenotic Cd · 2022 | Their institution | $2,769 |
| ABBVIE INC. · A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (Abt-494) in Participants With Crohns Disease Who Completed the Studies M14-431 Or M14-433 · 2022 | Their institution | $1,822 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1972892057
- Licence
- CA A122880California A122880: Current · expires 2028-08-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X)
- Mailing address
- 1701 Divisadero St, San Francisco, CA, 94115
- NPI first listed
- 2011-03-29
- NPI last updated
- 2019-03-20
This is when the NPI record was last certified, not a medical board exam.